期刊文献+

磷酸咯萘啶在小鼠体内的药动学过程 被引量:1

Study on Pharmaconkinetics of Pyronaridine in Mice
下载PDF
导出
摘要 研究磷酸咯萘啶在小鼠体内的药动学过程.小鼠一次性灌服磷酸咯萘啶后,用高效液相色谱法检测不同时间间隔血药浓度,计算药动学参数.小鼠一次灌胃1.56g.kg-1的磷酸咯萘啶后其药动学参数为:t1/2=(15.053±4.764)h,Tm ax=(6.072±0.834)h.结果表明,磷酸咯萘啶在小鼠体内药动学符合二房室开放模型,该方法准确可靠,操作简便,适用于药动学研究. This paper studies the pharmacokinetics of pyronaridine in mice and obtains pharmaeokinetic parameters. After a mouse is fed one time with pyronaridine, plasma concentrations are detected at different time point after ig single close of 1.56 g · kg^-1 with HPLC to calculate pharmacokinetic parameters. The pharmacokinetic parameters are determined after ig of pyronaridine ( 1.56 g · kg^-1) to mice. The main pharmacokinetic parameters of pyronaridine in mice were t1/2 = (15.053 ± 4.764) h, Tmax = (6.072 ± 0. 834) h. They all fit to the two-compartment open model. This experiment method satisfies the need for an accurate, sensitive, specific and convenient assay method in plasma for pharmaeokinefic studies of pyronaridine.
出处 《重庆工学院学报(自然科学版)》 2009年第7期48-50,共3页 Journal of Chongqing Institute of Technology
基金 重庆理工大学与重庆通天药业有限公司合作项目(2008Q23)
关键词 磷酸咯萘啶 药动学 高效液相色谱法 血药浓度 pyronaridine pharmacokinetic HPLC plasma comcentration
  • 相关文献

参考文献7

二级参考文献35

共引文献42

同被引文献23

  • 1杨恒林.恶性疟原虫对咯萘啶敏感性监测及临床研究现状[J].实用寄生虫病杂志,1997,5(1):34-36. 被引量:6
  • 2Ramharter M,Kurth F,Schreier AC,et al.Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparummalaria in pediatric patients in Gabon[J].The Journal of InfectiousDiseases,2008,198(6):911-919.
  • 3Price RN,Marfurt J,Chalfein F,et al.In vitro activity of pyronaridineagainst multidrug-resistant Plasmodium falciparum and Plasmodiumvivax[J].Antimicrobial Agents and Chemotherapy,2010,54(12):5146-5150.
  • 4Babacar Faye,Jean-Louis Ndiaye,Daouda Ndiaye,et al.Efficacy andtolerability of four antimalarial combinations in the treatment ofuncomplicated Plasmodium falciparum malaria in Senegal[J].Malaria Journal,2007,6:80-88.
  • 5DuttaGP,PuriSK,AwasthiA,et al.Pyronaridine:An effective antimalarialagainst multidrug-resistant malaria[J].Life Sciences,2000,67(7):759-763.
  • 6Park SH,Pradeep K.Absorption,Distribution,Excretion,and Pharmacokinetics of C-14-Pyronaridine Tetraphosphate in Male and FemaleSprague-Dawley Rats[J].J of Biomed&Biotechnol,2010,:590707.
  • 7Qi J,Yang CZ,Wang CY,et al.Function and mechanism of pyronaridine:a new inhibitor of P-glycoprotein-mediated multidrug resistance[J].Acta Pharmacol Sin,2002,23(6):544-550.
  • 8Petmitr P,Pongvilairat G,Auparakkitanon S,et al.Gametocytocidalactivity of pyronaridine and DNA topoisomerase II inhibitors againstmultidrug-resistant Plasmodium falciparum in vitro[J].Parasitol Int,2000,48(4):275-280.
  • 9抗疟药使用原则和用药方案(修订版).卫办疾控发(2009)106号.
  • 10Vivas L,Rattray L,Stewart L,et al.Anti-malarial efficacy of pyronaridineand artesunate in combination in vitro and in vivo[J].ActaTropica,2008,105(3):222-228.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部